BIO - BIO-RAD LABORATORIES, INC.

QQQ $ 455.25 $ 5.77 (1.29 %)

DIA $ 409.08 $ 4.58 (1.13 %)

SPY $ 546.60 $ 6.05 (1.12 %)

TLT $ 99.96 $ 0.43 (0.43 %)

GLD $ 231.58 $ 0.97 (0.42 %)

Previous Close

$ 323.09

Open

Bid

$ 322.81 x 200

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 261.59 - $ 384.37

Volume

485,150

Average Volume

Market Cap

Beta (5Y Monthly)

$ 0.87

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-02-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-16-2024	12-31-2023	10-K
4	10-27-2023	09-30-2023	10-Q
5	08-04-2023	06-30-2023	10-Q
6	05-05-2023	03-31-2023	10-Q
7	02-17-2023	12-31-2022	10-K
8	10-28-2022	09-30-2022	10-Q
9	07-29-2022	06-30-2022	10-Q
10	04-29-2022	03-31-2022	10-Q
11	02-11-2022	12-31-2021	10-K
12	10-29-2021	09-30-2021	10-Q
13	07-30-2021	06-30-2021	10-Q
14	04-30-2021	03-31-2021	10-Q
15	02-16-2021	12-31-2020	10-K
16	10-30-2020	09-30-2020	10-Q
17	07-31-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	03-02-2020	12-31-2019	10-K
20	11-01-2019	09-30-2019	10-Q
21	08-06-2019	06-30-2019	10-Q
22	05-10-2019	03-31-2019	10-Q
23	04-01-2019	12-31-2018	10-K
24	11-05-2018	09-30-2018	10-Q
25	08-09-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	04-16-2018	12-31-2017	10-K
28	11-09-2017	09-30-2017	10-Q
29	08-07-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	03-01-2017	12-31-2016	10-K
32	11-02-2016	09-30-2016	10-Q
33	08-05-2016	06-30-2016	10-Q
34	05-06-2016	03-31-2016	10-Q
35	02-29-2016	12-31-2015	10-K
36	11-05-2015	09-30-2015	10-Q
37	08-07-2015	06-30-2015	10-Q
38	05-06-2015	03-31-2015	10-Q
39	03-02-2015	12-31-2014	10-K
40	11-07-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

palantir-stock-soars-after-sp-500-inclusion-ai-deal-with-bp-fuels-additional-gains--whats-next

Palantir Stock Soars After S&P 500 Inclusi...
09/09/2024 14:10:18

Palantir (PLTR) stock surges due to inclusion in S&P 500 on Sept. 23 and new enterprise deal with BP. Technicals also show ...

Palantir Technologies, Dell Technologies, ...
09/06/2024 21:37:39

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20240906-1474143/1474143_septembershuffle546.pdf

Wells Fargo Initiates Coverage On Bio-Rad ...
08/27/2024 21:52:30

Wells Fargo analyst Brandon Couillard initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight rating and a...

Bio-Rad Appoints Jon DiVincenzo As Preside...
08/20/2024 12:40:25

Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announ...

RBC Capital Reiterates Outperform on Bio-R...
08/16/2024 15:15:56

RBC Capital analyst Conor McNamara reiterates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and maintains $401 price tar...

RBC Capital Maintains Outperform on Bio-Ra...
08/02/2024 19:48:27

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target f...

Citigroup Maintains Neutral on Bio-Rad Lab...
08/02/2024 16:19:07

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from...

Bio-Rad Expects FY24 Non-GAAP Revenue To D...
08/01/2024 20:18:32

Bio-Rad Laboratories Q2 2024 Adj. EPS $3.1...
08/01/2024 20:17:46

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $3.11 per share which beat the analyst consensus estimate of $2....

sp-500-ends-first-half-shy-of-all-time-highs-here-are-the-leaders-and-laggards--and-5-stocks-that-could-outperform-in-next-6-months

S&P 500 Ends First Half Shy Of All-Time Hi...
06/30/2024 22:02:19

The market's resilient run has made traders cautious of a potential correction, but analysts remain optimistic about its tr...

Jefferies Assumes Bio-Rad Laboratories at ...
06/03/2024 13:18:26

Jefferies assumes Bio-Rad Laboratories (NYSE:BIO) with a Hold rating and lowers Price Target of $315.

Federal Register Reported FDA Announcing R...
05/17/2024 11:04:17

-Reuters

The Analyst Landscape: 4 Takes On Bio-Rad ...
05/08/2024 15:00:24

UBS Maintains Buy on Bio-Rad Laboratories,...
05/08/2024 13:15:59

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $420 to $385.

Bio-Rad Maintains Its FY24 Financial Outlook
05/07/2024 20:24:16

The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 1.0 to 2.5 percent and an estimated ...

Bio-Rad Laboratories Q1 2024 Adj EPS $2.29...
05/07/2024 20:16:29

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $2....

Bio-Rad Laboratories Inc Reports 8.99% Pas...
04/22/2024 17:35:46

- SEC Filing

96-of-sp-500-stocks-show-upside-potential-vs-street-estimates-which-offers-the-best-opportunity

96% Of S&P 500 Stocks Show Upside Potentia...
04/18/2024 17:01:41

480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. ...

Oncocyte Announces Partnership Agreement W...
04/11/2024 21:32:54

The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more bro...

Bio-Rad Laboratories Says Andrew Last, Exe...
04/10/2024 20:16:58

Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a sea...